The EMA has appointed Grzegorz Cessak as its vice-chair of management for the next three years.
The European Medicines Agency (EMA) has appointed Grzegorz Cessak as vice-chair of its management for the next three years. Cessak has been president of Poland’s Office for registration of Medicinal Products, Medical Devices and Biocidal Products since July 2009, and a member of EMA’s Management Board since January 2010. He steps into the role that was vacated by Christa Wirthumer-Hoche following her election as chair in March 2016. In other news, the agency provided an update on its program to support the development of promising medicines addressing unmet medical needs (PRIME). A total of 48 applications were received between its launch on March 7, 2016 and the end of June, and about another 70 applications have been submitted since mid-2016. Overall, the number of new applications for marketing authorization received in the first half of 2016 was comparable to that received during the same period in 2015 (42 in the first half 2016 vs. 45 in the first half 2015). EMA also said it is developing a multilingual European medicines web portal that will aim to provide access to free, reliable, and unbiased information for patients, consumers, caregivers, healthcare professionals, and academics on all medicines authorized in the European Union (EU). The site will provide details about a medicine across its lifecycle, from clinical trials to adverse drug reaction reports. Read the full release here
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.